Table 1 Patients demographics and clinical characteristics at baseline
Doxorubicin, cyclophosphamide, docetaxel, trastuzumab plus pertuzumab (n = 40) | Doxorubicin, cyclophosphamide, docetaxel plus trastuzumab (n = 54) | P-value | |
|---|---|---|---|
Age in years (average ± standard deviation) | 45.4 ± 9.6 | 50.9 ± 9.9 | 0.008 |
Age group (n, %) | |||
≤ 24 | 1 (2.5%) | 0 (0.0%) | 0.068 |
25–29 | 0 (0.0%) | 1 (1.9%) | |
30–34 | 2 (5.0%) | 1 (1.9%) | |
35–39 | 8 (20.0%) | 7 (13.0%) | |
40–44 | 12 (30.0%) | 4 (7.4%) | |
45–49 | 5 (12.5%) | 12 (22.2%) | |
50–54 | 5 (12.5%) | 7 (13.0%) | |
55–59 | 3 (7.5%) | 12 (22.2%) | |
60–64 | 2 (5.0%) | 4 (7.4%) | |
≥ 65 | 2 (5.0%) | 6 (11.1%) | |
BMI (average ± standard deviation) | 25.5 ± 4.7 | 27.0 ± 5.7 | 0.168 |
ECOG performance status [20] (n, %) | |||
0 | 34 (85.0%) | 47 (87.0%) | 0.777 |
1 | 6 (15.0%) | 7 (13.0%) | |
Hormonal Receptors (ER and PR) (n, %) | |||
At least one positive | 27 (67.5%) | 32 (59.3%) | 0.414 |
Both negative | 13 (32.5%) | 22 (40.7%) | |
Clinical staging (n, %) | |||
IIA | 4 (10.0%) | 2 (3.7%) | 0.205 |
IIB | 8 (20.0%) | 8 (14.8%) | |
IIIA | 18 (45.0%) | 22 (40.7%) | |
IIIB | 10 (25.0%) | 17 (31.5%) | |
IIIC | 0 (0.0%) | 5 (9.3%) | |
Histologic grade (n, %) | |||
G1 | 0 (0.0%) | 1 (1.9%) | 0.640 |
G2 | 11 (27.5%) | 19 (35.2%) | |
G3 | 28 (70.0%) | 32 (59.2%) | |
Undetermined | 1 (2.5%) | 2 (3.7%) | |
At diagnosis (n, %) | |||
Operable | 24 (60.0%) | 15 (27.8%) | 0.001 |
Locally advanced | 6 (15.0%) | 26 (48.1%) | |
Inflammatory | 10 (25.0%) | 13 (24.1%) | |
Lymph node status (n, %) | |||
N0 | 4 (10.0%) | 10 (18.5%) | 0.006 |
N1 | 27 (67.5%) | 18 (33.3%) | |
N2 | 9 (22.5%) | 21 (38.9%) | |
N3 | 0 (0.0%) | 5 (9.3%) | |
Tumour size (n, %) | |||
T0 | 1 (2.5%) | 0 (0.0%) | 0.420 |
T1 | 2 (5.0%) | 2 (3.7%) | |
T2 | 13 (32.5%) | 11 (20.4%) | |
T3 | 14 (35.0%) | 21 (38.9%) | |
T4 | 10 (25.0%) | 20 (37.0%) | |